Company profile

Sartorius is a leading international partner for the biopharma sector. Our solutions are supporting our customers to develop and produce drugs safely, timely and economically. Founded in 1870, Sartorius currently employs around 14,100 people in more than 30 countries. Its operational business is subdivided into two divisions: Bioprocess Solutions and Lab Products & Services.

Key Figures

<table>
<thead>
<tr>
<th></th>
<th>H1 2024</th>
<th>Δ in %</th>
<th>H1 2023</th>
<th>FY 2023</th>
<th>FY 2022</th>
<th>FY 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales revenue (%Δ in const. fx)</td>
<td>1,680.3</td>
<td>-2.2</td>
<td>1,735.2</td>
<td>3,395.7</td>
<td>4,174.7</td>
<td>3,449.2</td>
</tr>
<tr>
<td>Order intake (%Δ in const. fx)</td>
<td>1,558.3</td>
<td>+8.5</td>
<td>1,449.6</td>
<td>3,066.9</td>
<td>4,007.3</td>
<td>4,267.9</td>
</tr>
<tr>
<td>Underlying EBITDA²</td>
<td>471.4</td>
<td>-8.8</td>
<td>516.7</td>
<td>962.7</td>
<td>1,410.4</td>
<td>1,175.0</td>
</tr>
<tr>
<td>Underlying EBITDA margin² in %</td>
<td>28.1</td>
<td>-1.7pp</td>
<td>29.8</td>
<td>28.3</td>
<td>33.8</td>
<td>34.1</td>
</tr>
<tr>
<td>Relevant net profit¹</td>
<td>148.4</td>
<td>-26.7</td>
<td>202.5</td>
<td>338.5</td>
<td>655.4</td>
<td>553.4</td>
</tr>
<tr>
<td>Underlying EPS per ordinary share³ in €</td>
<td>2.15</td>
<td>-27.3</td>
<td>2.95</td>
<td>4.94</td>
<td>9.57</td>
<td>8.08</td>
</tr>
<tr>
<td>Underlying EPS per preference share³ in €</td>
<td>2.16</td>
<td>-27.2</td>
<td>2.96</td>
<td>4.95</td>
<td>9.58</td>
<td>8.09</td>
</tr>
<tr>
<td>Equity ratio⁴ in %</td>
<td>38.3</td>
<td>-0.1pp</td>
<td>38.4</td>
<td>28.3</td>
<td>38.1</td>
<td>30.2</td>
</tr>
<tr>
<td>Net debt to underlying EBITDA⁵</td>
<td>4.4</td>
<td>-</td>
<td>2.1</td>
<td>5.0</td>
<td>1.7</td>
<td>1.5</td>
</tr>
</tbody>
</table>

1. All customer orders contractually concluded and booked during the respective reporting period.
2. Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items
3. Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.
4. Equity in relation to the balance sheet total
5. Quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period

Sales Revenue by Division 2023

Bioprocess Solutions ~79%
Lab Products & Services ~21%

~€3.40bn

Sales Revenue by Region 2023

Americas 38%
EMEA 39%
Asia | Pacific 23%

EMEA = Europe | Middle East | Africa

Earnings per Share¹ in €

<table>
<thead>
<tr>
<th></th>
<th>2019</th>
<th>2020</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary shares (SRT)</td>
<td>3.07</td>
<td>4.38</td>
<td>8.09</td>
<td>9.58</td>
<td>4.95</td>
</tr>
<tr>
<td>Preference shares (SRT3)</td>
<td>3.06</td>
<td>4.37</td>
<td>8.08</td>
<td>9.57</td>
<td>4.94</td>
</tr>
</tbody>
</table>

2024 Guidance¹²

<table>
<thead>
<tr>
<th></th>
<th>Sales Revenue Growth (in %)</th>
<th>EBITDA-Margin²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sartorius Group</td>
<td>on prior-year level with bandwith of +/- lsd % growth</td>
<td>27 to 29%</td>
</tr>
<tr>
<td>Bioprocess Solutions</td>
<td>on prior-year level with bandwith of +/- lsd % growth</td>
<td>28 to 30%</td>
</tr>
<tr>
<td>Lab Products &amp; Services</td>
<td>on prior-year level with bandwith of +/- lsd growth</td>
<td>22 to 24%</td>
</tr>
</tbody>
</table>

Capex Ratio ~12.0%

1. After non-controlling interest, adjusted for extraordinary items as well as amortization, and based on a normalized financial result and the normalized tax rate
2. As of July 18, 2024
3. Underlying = excluding extraordinary items

Investment Highlights

1. Focus on the high-growth biopharma market
2. Broad and differentiating product offering
3. Strong global presence
4. High share of recurring business; significant market entry barriers
5. Proven track record with alliances and acquisitions;
6. High continuity with respect to customer base, employees and management
Division Strategy

**Bioprocess Solutions**
- Positioned as a total solution provider for the biopharma industry with a product portfolio covering nearly all steps of the customers' production processes
- Global leading positions in key technology platforms; e.g. process filtration, fluid management, fermentation and cell cultivation
- One of the widest portfolios in the industry; clear focus on single-use technologies such as filters, bags and cell culture media
- Continuous expansion through complementary acquisitions and targeted alliances

**Lab Products & Services**
- Premium provider of laboratory instruments, consumables and services for sample preparation and bioanalytic
- Leading international positions in laboratory balances, pipettes and lab consumables
- Outstanding brand reputation, strong product range and global services as the basis for further expansion of market share
- Extension of portfolio with complementary laboratory products through acquisitions and alliances

**Facts about Preference Shares**

Ticker symbol: SRT3
Ticker symbol Bloomberg: SRT3 GY
Ticker symbol Reuters: SATG_pe.DE
WKN | ISIN: 716 563 | DE0007165631

**Facts about Ordinary Shares**

Ticker symbol: SRT
Ticker symbol Bloomberg: SRT GY
Ticker symbol Reuters: SATG
WKN | ISIN: 716 560 | DE0007165607

---

**Sartorius Shares in Comparison (indexed)**

<table>
<thead>
<tr>
<th>Date Range</th>
<th>Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>July 1, 2023, to June 30, 2024</td>
<td>150%</td>
</tr>
</tbody>
</table>

---

**Shareholder Structure: Ordinary Shares**

June 30, 2024
- Administred by an executor ~55%
- Bio-Rad Laboratories Inc. ~38%
- Free float ~7%

**Shareholder Structure: Preference Shares**

June 30, 2024
- Bio-Rad Laboratories Inc. ~28%
- Free float ~72%

The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders' own disclosures. The legal disclosure requirements refer only to ordinary shares and not to non-voting preference shares.

---

**Financial calendar**

October 17, 2024
Publication of Quarterly Statement Jan. - Sep. 2024

---

**Disclaimer**

This fact sheet contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize. This is because our assumptions harbour risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements. Throughout this fact sheet, differences may be apparent as a result of rounding during addition.

---

Petra Kirchhoff
Head of Corporate Communications
Tel.: +49.551.308.1686
Email: petra.kirchhoff@sartorius.com

Petra Müller
Head of Investor Relations
Tel.: +49.551.308.6035
Email: petra.mueller2@sartorius.com